Description: Review the benefits of branded Letairis, including efficacy, safety, and co-pay support. View Important Safety Information, including BOXED WARNING.
Letairis (ambrisentan) is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening; and in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.
Help your eligible patients pay as little as $5 per month †
Prescribe Letairis DAW ‡ to help ensure the brand you choose is what your patient receives